Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00368173
Other study ID # INSM-110-303
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received August 23, 2006
Last updated September 11, 2012

Study information

Verified date September 2012
Source Insmed Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

STUDY OBJECTIVE

To evaluate the safety, tolerability, and efficacy, as growth velocity (statural growth), of rhIGF-I/rhIGFBP-3 administered for 12 months in pre-pubertal children and adolescents with GHIS.

STUDY DESIGN

This study is an open-label, multi-center clinical trial to evaluate the safety and effectiveness of rhIGF-I/rhIGFBP-3 to increase rate of growth when administered once daily for 12 months in children and adolescents with growth hormone insensitivity syndrome (GHIS) such as Laron Syndrome. At the end of the initial twelve-month treatment period, additional safety and long-term efficacy data will be assessed in a second 12 month treatment period.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria:

1. A diagnosis of GHIS such as Laron syndrome,

2. 2 - 18 years of age,

3. Height less than or equal to -3SD for age,

4. Pre-pubertal, defined as Tanner breast stage 1 or testis volume <4mL

Exclusion Criteria:

1. Children in puberty,

2. Diagnosed malignancy,

3. A diagnosis of diabetes mellitus

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
rhIGF-I/rhIGFBP-3


Locations

Country Name City State
Argentina Dr. Alicia Belgorosky Buenos Aires
Argentina Dr. Christina Bazan Tucuman
Australia Dr. Bruce King Newcastle
Brazil Dr. Durval Damiani Sao Paulo
China Dr. Kwok-leung NG Hong Kong
Egypt Dr. Mohamed EL Kholy Cairo
Germany Professor Annette Greuters Berlin
Israel Tiosano Dov Haifa
Italy Maria Carolina Salerno Naples
Norway Dr. Hilde Bjorndalen Oslo
Peru Dr. Carlos del Aguila Lima
Slovakia Dr. Magdalena Paskova Kosice
Turkey Professor Nursen Yordam Ankara
United Kingdom Dr. Cecilia Camacho-Hubner London
United States Robert Rapaport, MD New York New York

Sponsors (1)

Lead Sponsor Collaborator
Insmed Incorporated

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  China,  Egypt,  Germany,  Israel,  Italy,  Norway,  Peru,  Slovakia,  Turkey,  United Kingdom,